We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drug company spending on direct-to-consumer (DTC) advertising will continue to increase, although drugmakers are worried about potential legislation that would restrict the advertisements, research company Guideline said in a new report.
Amgen’s clinical program to expand Vectibix’s use as a first- and second-line treatment for metastatic colorectal cancer is not affected by the discontinuation of the Avastin-Vectibix combination trial, which was halted due to efficacy and safety concerns.
Federal lawmakers should grant adequate funding to the NIH to sustain advances in modern medicine, members of the academic biomedical science and research community said.
Federal policymakers should ensure the FDA has adequate resources in order to review and approve follow-on biologics in a timely and effective manner, according to American Enterprise Institute (AEI) Research Fellow Scott Gottlieb.
A study claiming that two state pharmaceutical gift disclosure laws do not make payment information easily available to the public relied on inconsistent and mixed data, a top PhRMA official said.
A new Medicaid rule being proposed by the Centers for Medicare & Medicaid Services (CMS) could discourage generic drug use and should be amended to reflect actual acquisition costs for retailers that fill prescriptions with generic drugs, a pharmacist group said.
Despite lower fourth-quarter income due to generic competition for one of its top products, Savient Pharmaceuticals saw significant earnings in 2006, according to financial results released by the company.